久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國Mersana Therapeutics
Mersana 是一家未公開上市的由風險投資做為后盾 (venture-backed) 的企業。該公司正在通過使用 Fleximer(R) 開發基于臨床驗證藥物的新型抗腫瘤藥劑。Fleximer(R) 是一種獲得專利的生物可降解與生物惰性物質，能增強藥物的藥物代謝動力、安全性和溶解性。Mersana 擁有來自 Massachusetts General Hospital 對其核心技術的獨家授權。Mersana 研發的產品系列中包含一些已經通過其專利技術而得到改進的復方藥，這些復方藥具有抗多種癌癥的活性，并在人體實驗中得到了證明。Mersana 的投資方包括 Fidelity Biosciences、ProQuest Investments、Rho Ventures、Harris & Harris Group 和 PureTech Ventures。

Fleximer 技術能通過把生物降解能力和“生物暗中作用”特性獨特地結合起來，改善可有效用作抗癌藥劑的細胞毒素復方藥物的治療指數，從而使 Fleximer(R) 物質與其共軛物體的具有長的循環周期且成為非免疫毒素療法 (non-immunotoxic)。Fleximer 分子具有如下特點：可溶于水、在一般的生產過程和正常生理狀態下很穩定，同時具有細胞攝入時不涉及酶作用的生物降解能力。


Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules.

?

Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. Utilizing our technology, we are developing a portfolio of next-generation antibody-drug conjugates (ADC) with superior properties not found with current ADC technologies. Our clinical pipeline consists of two cancer therapeutics with blockbuster potential. XMT-1001 is a potentially best-in-class novel "tecan" conjugate that is currently being investigated in a Phase 1b extension trial in patients with lung cancers. XMT-1107 is a first-in-class anti-angiogenic conjugate with a unique mechanism of action that is currently in a Phase 1 trial in patients with refractory, advanced solid tumors. XMT-1107 was licensed to Teva on a worldwide basis except for Japan, where Mersana elected to retain rights. These clinical candidates reflect the successful application of our unique conjugation system.

?

This versatile conjugation system integrates Fleximer?, a clinically validated biodegradable polymer, with a broad array of customized linker chemistries designed to control conjugation, stability and release of diverse classes of therapeutic payloads. This system provides important benefits required for the development of next-generation drugs across therapeutic modalities, including ADCs, antibody fragments, small molecules, biologics and siRNA, as well as synergistic drug combinations. Mersana's approach results in completely novel drugs with intellectual property protection and extended patent life, via novel composition-of-matter.

?

Our technology is being leveraged in multiple therapeutic areas through partnerships. Mersana is interested in pursuing technology-enabling and proprietary drug candidate-based opportunities with partners interested in accessing our cutting-edge, clinically validated drug conjugation system.

?